| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for AtheroGenics, Inc. > News item |
AtheroGenics, Astellas extend collaboration for organ transplant rejection agent
By Lisa Kerner
Erie, Pa., Feb. 2 - AtheroGenics, Inc. and Astellas Pharma Inc. extended their research and development collaboration for AGI-1096, according to a company news release.
AGI-1096 is a novel antioxidant and selective anti-inflammatory investigational agent discovered by AtheroGenics. This compound is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
AtheroGenics and Astellas will continue to explore the therapeutic utility of AGI-1096 in this indication. Astellas will fund all of the development costs during the extended term of the agreement and will retain the exclusive option to negotiate for late stage development and commercial rights to the compound, the company said.
In a phase 1clinical trial of oral AGI-1096 in combination with Astellas' tacrolimus (Prograf) conducted in healthy volunteers, results indicated that regimens of AGI-1096 administered alone, and concomitant with tacrolimus, were generally well-tolerated. There were no serious adverse events associated with either regimen during the course of the study.
"The phase 1 study with tacrolimus is the first controlled study to evaluate the safety and tolerability of AGI-1096 in healthy volunteers in combination with another oral therapy for the prevention of organ transplant rejection," stated Rob Scott, senior vice president of clinical development and regulatory affairs and chief medical officer of AtheroGenics, in the release.
Atlanta-based AtheroGenics discovers, develops and commercializes novel drugs for the treatment of chronic inflammatory diseases.
Astellas Pharma is a Tokyo-based pharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.